AVH owns the patents and produces a medical device called RECELL, which produces a “suspension” of spray-on skin cells using a small sample of the patient’s own skin to help treat burn patients and skin defects.
In September 2018, the company received FDA approval for use of RECELL to treat patients with acute and severe burns for patients over 18 and began supplying in 2019
Why is it so good?
Results are better than current skin grafting
Cheaper – they sell it for $7.5k and works out be ~$4/cm2 compared to other options $28-$60/cm2
Less painful for the patient
Currently approved for acute thermal burns in adults but working on and looking to advance to:
Approval for use for Paediatrics – where trials have commenced in late 2018. AVH has already used the device on paediatrics in previous trials for compassionate use
Chronic wounds – including venous leg and diabetic foot ulcersHypopigmentation – vitiligo and scars
Trauma wounds
So the runway is huge.
